Drug profile · INN
ozanimod
ZEPOSIA
ozanimod (ZEPOSIA) is a sphingosine 1-phosphate receptor edg-1 modulator. Associated with Bristol-Myers Squibb Australia Pty Ltd. Current US regulatory status: approved.
Drug details — ozanimod
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
ozanimod (ZEPOSIA) is a sphingosine 1-phosphate receptor edg-1 modulator. Associated with Bristol-Myers Squibb Australia Pty Ltd. Current US regulatory status: approved.
Key facts
Mechanism of action
Sphingosine 1-phosphate receptor Edg-1 modulator
Primary target: Sphingosine 1-phosphate receptor 5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ozanimod?
ozanimod (ZEPOSIA) is a sphingosine 1-phosphate receptor edg-1 modulator. Associated with Bristol-Myers Squibb Australia Pty Ltd. Current US regulatory status: approved.
What is the brand name for ozanimod?
ZEPOSIA is a marketed brand name for ozanimod. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ozanimod?
ozanimod has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.